Macrocycles: Big Is the New Beautiful

Why It Matters

The surge in macrocycle platforms promises to unlock treatments for targets that have eluded conventional drugs, reshaping pipelines for pharma and biotech investors alike.

Key Takeaways

• Macrocycles bridge small molecules and biologics with oral potential
• Orbis's nGen platform screens billions, targeting oral bioavailability
• Curve Therapeutics raised $51.5M Series A, advancing intracellular pipelines
• Novartis invests up to $1.7B in macrocycle collaborations
• AI and DNA‑encoded libraries speed macrocycle design and screening

Pulse Analysis

The resurgence of macrocycles reflects a convergence of chemistry and computation that finally overcomes the synthesis bottlenecks that plagued early attempts. Natural macrocycles like cyclosporine demonstrated therapeutic power, yet synthetic analogues struggled with permeability and oral dosing. Modern high‑throughput platforms, bolstered by machine‑learning models, can predict conformational rigidity and membrane crossing, allowing researchers to design molecules that fit flat protein surfaces while retaining drug‑like pharmacokinetics.

In Europe, Orbis Medicines and Curve Therapeutics exemplify how capital and technology are accelerating this modality. Orbis’s nGen system leverages billions of virtual structures, rapidly narrowing them to a few hundred high‑quality candidates for oral delivery. Curve’s Microcycle® library, screened inside living cells, uncovers intracellular hits that traditional biologics cannot reach. The recent $51.5 million Series A raise for Curve and a $1.7 billion deal between Novartis and Unnatural Products underscore the confidence investors have in macrocycle pipelines that promise first‑in‑class mechanisms.

Globally, major pharmaceutical players are forging partnerships to embed macrocycle programs into their portfolios, recognizing the strategic advantage of a modality that can address protein‑protein interactions, oncology, immunology, and cardiovascular disease with oral convenience. As late‑stage clinical data emerge, macrocycles are poised to transition from niche curiosities to mainstream therapeutics, potentially reshaping market dynamics and creating new revenue streams for companies that master this hybrid chemistry.